Download - MIOPATI UISU 2010
![Page 1: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/1.jpg)
MyopathiesMyopathies
Aldy S. Rambe
![Page 2: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/2.jpg)
General Considerations
Myopathy means a primary disorder of muscle causing wasting and/or weakness in the absence of sensory abnormalities
Can result from a variety of inherited and acquired disorders.
Pattern of weakness remain similar despite the broad spectrum of etiologies.
Detailed family history, broad systemic reviews, and careful drug history are mandatory.
![Page 3: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/3.jpg)
ESSENTIALS of DIAGNOSISESSENTIALS of DIAGNOSIS
Weakness greater proximally than distally (myopathic distribution)
Normal sensation Normal sphincter function Relative preservation of deep tendon reflexes Muscle biopsy is often definitive Genetic testing can confirm diagnosis of hereditary
disorders caused by specific mutations.
![Page 4: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/4.jpg)
Muscular DystrophiesMuscular Dystrophies
Muscular dystrophies are myopathies that tend to be prgressive with ongoing degeneration and regeneration and fatty infiltration of muscle fibers.
![Page 5: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/5.jpg)
DUCHENNE MUSCULAR DUCHENNE MUSCULAR DYSTROPHYDYSTROPHY The most common muscular dystrophy Prevalence : 1 : 3500 male births Almost always in male, while female are carriers X-linked recessive disorders 1st case was reported in Italy in 1836, and in 1852 was
recognized and described as an inherited disorder of boys by the english physician Meryon.
In DMD no dystrophin is found in muscle or other body tissue cell walls.
![Page 6: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/6.jpg)
![Page 7: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/7.jpg)
DMD – Clinical Patterns DMD – Clinical Patterns
Typically infants with DMD are thought to have no physical problems.
Muscle weakness is usually first recognized between ages 3 and 5 years. It progress symmetrically and linearly until age 14, when progression slows and occurs in a predictable pattern, with extensor muscles being weaker than flexor muscles.
Children tend to walk on their toes from outset and may never be able to walk with the feet flat (toe walking)
![Page 8: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/8.jpg)
DMD – Clinical Patterns (cont.c)DMD – Clinical Patterns (cont.c)
They also tend to waddle (waddling gait) and have to climb up their legs, thighs and hips when getting up from the floor or from a chair (Gower’s sign).
The ability to run is not attained. Walking velocity begins to decrease linearly between ages 4 and
6 and is about 29% of normal by age 10. Patients developed an imbalance in muscle strength at every
joint. Flexors remain stronger extensors. This lead to musculotendinous contractures and loss of joint range of motion. The stronger muscles on one side of the joint stretch their weaker antagonists cause the weaker muscles get weaker even faster because they are no longer at their ideal length for contracting.
![Page 9: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/9.jpg)
GOWER’S SIGN
![Page 10: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/10.jpg)
CALF PSEUDOHYPERTROPHY
![Page 11: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/11.jpg)
TOE WALKING
![Page 12: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/12.jpg)
DIAGNOSISDIAGNOSIS
Elevated muscle enzymes level :CK, AST, ALT, LDH, aldolasecreatinuria, myoglobinuria
Abnormal ECG : tachycardia, RBBB, Q wave Abnormal EMG : short-duration, small-amplitude
motor unit potentials with early recruitment (so-called myopathic features)
DNA analysis : mutation Muscle biopsy
Microsoft:Microsoft:
![Page 13: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/13.jpg)
THERAPYTHERAPY
NO specific treatmentPrednisone 0.75 g/kb/day significant
increase in muscle strength and prolong ambulation up to 3 years.
Deflazacort 0.9 mg/kg/day lower side effects
Physical therapy, bracing, orthoses, and orthopaedic surgery are often required
![Page 14: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/14.jpg)
Becker Muscular DystrophyBecker Muscular Dystrophy
X-linked recessive disorder A milder allelic form of DMD, with decreased or
altered dystrophin rather than absence. Onset usually after 12 yearsof age, and delayed
onset after the 4th decade is occasionallly seen Limb-girdle weakness is typical Cardiac involvement may occur Mental retardation is rare
![Page 15: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/15.jpg)
Becker Muscular Dystrophy (cont.d)Becker Muscular Dystrophy (cont.d)
Life expectancy is reduced Most survive into the 4th or 5th decade The clinical approach is similar to DMD
![Page 16: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/16.jpg)
DRUG-INDUCED MYOPATHYDRUG-INDUCED MYOPATHY
Mechanism of drug-induce myopathy Drug MechanismCholesterol lowering agent NecrosisCosticosteroids Fiber atrophyDiuretics Metabolic disturbancesD-Penicillamine, L-Tryptophan InflammationEmetine, amiodarone, colchicine, Vacuolar changesand chloroquineVaccines adjuvants containing MacrophagicAluminium hydroxide myofasciitisValproic acid Carnitine deficiencyZidovudine Mitochondrial dysfunction
![Page 17: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/17.jpg)
CORTICOSTEROID MYOPATHYCORTICOSTEROID MYOPATHY
ESSENTIALS of DIAGNOSIS : Slowly progressive proximal weakness (most common) Rapidly progressive weakness in some patients (rare) Follows long-term treatment with corticosteroid doses
greater than 30 mg/day Cushingoid appearance Serum CK level is usually normal Normal findings on EMG, or myopathic features without
spontaneous activity Muscle biopsy evidence of type 2b fiber myopathy
![Page 18: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/18.jpg)
CHOLESTEROL-LOWERING AGENT CHOLESTEROL-LOWERING AGENT MYOPATHYMYOPATHY
Every agents including statins, niacin, clofibrate, and
gemfibrozil has myotxic effects.
ESSENTIALS of DIAGNOSIS :
Exposure to cholesterol-lowering agentsMyalgiasProximal muscle weakness
![Page 19: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/19.jpg)
CHANNELOPATHIESCHANNELOPATHIES
Channelopathies are rare diseases caused by functional
disturbances of ion channel proteins as a result of specific
mutations. These disorders include the familial periodic
paralyses and disorders with myotonia
ESSENTIALS of DIAGNOSIS : Inherited disorder Weakness (episodic), myotonia, or both Precipitating factors are usually identifiable
![Page 20: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/20.jpg)
CHANNELOPATHIESCHANNELOPATHIES
1. Hypokalemic periodic paralysis *2. Hyperkalemic periodic paralysis *3. Paramyotonia congenita *4. Myotonia congenita (Thomsen) *5. Generalized myotonia (Becker) **6. Malignant Hyperthermia * * autosomal dominant inheritance** autosomal recessive inheritance
![Page 21: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/21.jpg)
HYPOKALEMIC PERIODIC PARALYSISHYPOKALEMIC PERIODIC PARALYSIS
Type 1 Ca channel defect, type 2 Na channel defect Onset : puberty to third decade Clinical findings :
* episodic attacks of weakness (presence, typical duration, severity)
* normal or mildly elevated serum CK level during attack
* myotonia confined to eyelids
* no muscle hypertrophy
![Page 22: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/22.jpg)
HYPOKALEMIC PERIODIC PARALYSISHYPOKALEMIC PERIODIC PARALYSIS
Precipitating factors : carbohydrate load, postexercise period, pregnancy, emotional stress, cold.
Treatment :* Potassium chloride 0,25 mEq/kg PO (may repeat
every 30 minutes until weakness subsides)* Avoid IV potassium because of risk of uncontrollable hyperkalemia
Prophylaxis :* Acetazolamide ; titrate up to 3 x 250 mg/day* Dichlorphenamide ; 3 x 25 mg/day
![Page 23: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/23.jpg)
DISORDERS OF THE DISORDERS OF THE NEUROMUSCULAR JUNCTIONNEUROMUSCULAR JUNCTIONMyasthenia GravisLambert-Eaton Myasthenic Syndrome Congenital Myasthenic SyndromesBotulismTick Paralysis
![Page 24: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/24.jpg)
MYASTHENIA GRAVISMYASTHENIA GRAVIS
The most common NMJ disorders Acquired, predominantly antibody-mediated autoimmune
disease Ab are targeted against the nicotinic AChR at NMJ
overall reduction in the number of AChR and damage to the postsynaptic membrane
Prevalence 1 : 10.000 - 20.000 people. Male : fifth and sixth decade Female : second and third decade
![Page 25: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/25.jpg)
PATHOGENESISPATHOGENESIS
In generalized MG, Ab (+) in up o 90%, in purely ocular MG, only about 50% Ab (+)
Ab cross-link the AChRs and facilitate unusually rapid endocytosis receptor loss on postsynaptic membrane
Complement-mediated damage to the membrane results in fewer membrane folds and widened synaptic cleft.
The Ab production is a T-cell-mediated process thoght to be associated with thymic dysfunction.
Thymic hyperplasia - 70% MG ; Thymoma – 10% MG
![Page 26: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/26.jpg)
ACETHYLCHOLINE SYNTHESIS
![Page 27: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/27.jpg)
![Page 28: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/28.jpg)
CLASSIFICATIONCLASSIFICATION
Group 1 : ocular myasthenia
Group 2 : mild generalized myasthenia
Group 3 : severe generalized myasthenia
Group 4 : crisis myasthenia
![Page 29: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/29.jpg)
CLINICAL FINDINGSCLINICAL FINDINGS
Clinical characteristics : fluctuating, fatigable weakness of commonly used muscles.
Hallmark features : ptosis, diplopia, dysarthria, dysphagia, respiratory and limb muscles weakness.
50% presents with ocular findings. Ocular muscles weakness usually bilateral and asymmetric
and result in ptosis, diplopia or both. The pupil is spared. Almost all MG develop ocular symptoms, in some limited
to the extraocular muscles
![Page 30: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/30.jpg)
PtosisPtosis
![Page 31: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/31.jpg)
DIAGNOSTIC STUDIESDIAGNOSTIC STUDIES
1. Tensilon (edrophonium) test2. Prostigmin test3. Laboratory studies :
serologic testing : AChR-binding Ab (most sensitive) AChR-modulating Ab AChR-blocking Ab
4. Electrodiagnostic studies : slow repetitive nerve stimulation
5. Imaging and other studies : CT or MRI scan of the chest
![Page 32: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/32.jpg)
TREATMENTTREATMENT
A. Symptomatic Treatment :
cholinesterase inhibitors which increase the
concentration of Ach at the AChR.
Eg. : Pyridostigmine bromide, up to 600 mg/day PO
Ambenomium, 5 – 25 mg PO 3-4 x/day,
max 200 mg/day
Neostigmine, up to 150 mg/day PO
![Page 33: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/33.jpg)
TREATMENTTREATMENT
B. Immunosupressive Treatment :
1. Thymectomy :
* most effective during the first 2 years of disease
* should be considered at any age of MG
* necessary in neoplastic thymoma
* in patients without thymoma, thymectomy increase the likelihood of remission
* best surgical procedure debatable
![Page 34: MIOPATI UISU 2010](https://reader030.vdocuments.mx/reader030/viewer/2022032515/563db92d550346aa9a9ac5ed/html5/thumbnails/34.jpg)
TREATMENTTREATMENT
2. Medical Therapy.a. Corticosteroid : first line agent.b. Nonsteroidal immunosuppression :
* Azathioprine* Mycophenolate mofetil* Cyclosporine
c. Short-term treatment :Plasmapharesis or IVIGinduce rapid clinical improvement but have only short-term effects